Pheast Therapeutics develops checkpoint therapies to harness the innate immune system.
Pheast Therapeutics has raised $76.0M in total funding. The most recent round was Series A. The last funding was announced in April 2022.
Pheast Therapeutics's investors include ARCH Venture Partners, Catalio Capital Management, Alexandria Venture Investments, Risk & Reward Group.
Pheast Therapeutics is headquartered in Palo Alto, United States.
Pheast Therapeutics develops checkpoint therapies to harness the innate immune system.
Pheast Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Pheast Therapeutics — Funding & Investors." VCBacked, April 26, 2022, https://www.vcbacked.co/company/pheast-therapeutics. Accessed October 22, 2026.
VCBacked. (2022). Pheast Therapeutics — Funding & Investors. Retrieved October 22, 2026, from https://www.vcbacked.co/company/pheast-therapeutics
{{cite web |title=Pheast Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/pheast-therapeutics |website=VCBacked |access-date=October 22, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated